查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595147

PD-1 和 PD-L1 抑制劑市場：按產品、分銷管道 - 2025-2030 年全球預測

PD-1 & PD-L1 Inhibitors Market by Product (Atezolizumab, Avelumab, Durvalumab), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

PD-1和PD-L1抑制劑市場2023年估值為371.1億美元，預計2024年將達到446.1億美元，複合年成長率為20.59%，到2030年預計將達到1376.5億美元。

程序性死亡 1 (PD-1) 和程序性死亡配體 1 (PD-L1) 抑制劑在各種癌症的治療中至關重要，因為它們有助於重新運作免疫系統來攻擊癌細胞。對這些抑制劑的需求源自於為對傳統治療沒有反應的患者提供治療選擇的能力，代表著向個人化醫療的轉變。它的用途涵蓋多種癌症，包括黑色素瘤、非小細胞肺癌和腎細胞癌。最終用途包括從事創新癌症治療方法的醫院、診所和研究機構。 PD-1 抑制劑和 PD-L1 抑制劑市場受到全球癌症發生率上升、研究經費增加以及免疫療法意識不斷增強的推動。共同開發和商業化新抑制劑的策略聯盟和合作研究也在成長中發揮重要作用。新的商機在於探索可以提高療效和擴大覆蓋範圍的聯合治療。然而，高治療成本、監管挑戰以及限制患者採用的潛在副作用阻礙了成長。競爭格局非常激烈，需要大量的研發投資才能保持競爭力。創新成長領域包括開發具有改進的安全性和功效的下一代抑制劑，以及研究生物標記以更好地進行患者分層和治療客製化。公司應專注於將其地理足跡擴展到醫療保健基礎設施正在改善的新興市場，並採取使治療更便宜的策略。市場競爭非常激烈，我們面臨著快速的技術進步，因此保持研究的前沿並保持經營模式的敏捷性是關鍵。策略建議包括投資個人化醫療解決方案的研發、確保策略合作夥伴關係以及透過具成本效益的生產和分銷管道加強市場進入。

主要市場統計
基準年[2023] 371.1億美元
預測年份 [2024] 446.1億美元
預測年份 [2030] 1376.5億美元
複合年成長率（%） 20.59%

市場動態：揭示快速發展的 PD-1 和 PD-L1 抑制劑市場的關鍵市場洞察

PD-1 和 PD-L1 抑制劑市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 隨著老年人口的增加，癌症的盛行率也增加
    • 患者援助計畫不斷增加
    • 公眾意識的提高和醫療費用的上漲
  • 市場限制因素
    • 癌症免疫治療費用高昂
  • 市場機會
    • 活性化PD1 和 PDL1 抑制劑的研究活動
    • 癌症篩檢方法的創新與進展
  • 市場問題
    • 嚴格監管場景

波特五力：駕馭 PD-1 與 PD-L1 抑制劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 PD-1 和 PD-L1 抑制劑市場的外部影響

外部宏觀環境因素在塑造 PD-1 和 PD-L1 抑制劑市場的業績動態發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解PD-1和PD-L1抑制劑市場的競爭格局

PD-1 和 PD-L1 抑制劑市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：PD-1 和 PD-L1 抑制劑市場供應商的績效評估

FPNV定位矩陣是評估PD-1和PD-L1抑制劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃 PD-1 和 PD-L1 抑制劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 PD-1 和 PD-L1 抑制劑市場進行策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率增加和老年人口數量增加
      • 擴大患者支持計劃
      • 公眾意識的提高和醫療費用的上漲
    • 抑制因素
      • 癌症免疫治療費用高昂
    • 機會
      • PD1 和 PDL1 抑制劑的研究活動增加
      • 癌症檢測技術創新與進展
    • 任務
      • 嚴格監管場景
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 PD-1 和 PD-L1 抑制劑市場：依產品

  • 介紹
  • Atezolizumab
  • Avelumab
  • Durvalumab
  • 納武單抗
  • Pembrolizumab

第 7 章 PD-1 與 PD-L1 抑制劑市場：依通路

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章美洲PD-1和PD-L1抑制劑市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太PD-1和PD-L1抑制劑市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲PD-1和PD-L1抑制劑市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Akeso Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Innovent Biologics Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
Product Code: MRR-4659C8713636

The PD-1 & PD-L1 Inhibitors Market was valued at USD 37.11 billion in 2023, expected to reach USD 44.61 billion in 2024, and is projected to grow at a CAGR of 20.59%, to USD 137.65 billion by 2030.

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are pivotal in the treatment landscape for various cancers as they help in reactivating the immune system to attack tumor cells. The necessity of these inhibitors arises from their ability to provide therapeutic options to patients who may not respond to traditional treatments, signifying a shift towards personalized medicine. Their application spans across numerous cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others. The end-use scope involves hospitals, clinics, and research institutes working towards innovative cancer treatment modalities. The market for PD-1 and PD-L1 inhibitors is primarily driven by the rising incidence of cancer globally, increased research funding, and the growing awareness about immunotherapies. Strategic partnerships and collaborations for co-development and commercialization of novel inhibitors also play a crucial growth role. Emerging opportunities lie in exploring combination therapies, which could enhance efficacy and extend their application scope. However, growth is impeded by high treatment costs, regulatory challenges, and potential side effects that can limit patient adoption. The competitive landscape is challenging with significant R&D investments needed to stay competitive. Innovational growth areas include the development of next-generation inhibitors with improved safety profiles and efficacy, as well as research into biomarkers for better patient stratification and treatment customization. Businesses should focus on expanding their geographical footprint into emerging markets where healthcare infrastructure is improving and adopting strategies to make treatments more affordable. As the market is competitive and subject to rapid technological advancements, staying at the forefront of research and maintaining agility in business models will be key. Strategic recommendations include investing in R&D for personalized medicine solutions, securing strategic collaborations, and enhancing market accessibility through cost-effective production and distribution channels.

KEY MARKET STATISTICS
Base Year [2023] USD 37.11 billion
Estimated Year [2024] USD 44.61 billion
Forecast Year [2030] USD 137.65 billion
CAGR (%) 20.59%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PD-1 & PD-L1 Inhibitors Market

The PD-1 & PD-L1 Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer coupled with growing geriatric population
    • Growing presence of patient assistance programs
    • Rising public awareness and increasing healthcare expenses
  • Market Restraints
    • High cost of cancer immunotherapy
  • Market Opportunities
    • Increasing research activities in pd1 and pdl1 inhibitors
    • Technological innovations and advancements in cancer screening procedures
  • Market Challenges
    • Stringent regulatory scenario

Porter's Five Forces: A Strategic Tool for Navigating the PD-1 & PD-L1 Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PD-1 & PD-L1 Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PD-1 & PD-L1 Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PD-1 & PD-L1 Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PD-1 & PD-L1 Inhibitors Market

A detailed market share analysis in the PD-1 & PD-L1 Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PD-1 & PD-L1 Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PD-1 & PD-L1 Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PD-1 & PD-L1 Inhibitors Market

A strategic analysis of the PD-1 & PD-L1 Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PD-1 & PD-L1 Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca PLC, BeiGene Ltd., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Innovent Biologics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the PD-1 & PD-L1 Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer coupled with growing geriatric population
      • 5.1.1.2. Growing presence of patient assistance programs
      • 5.1.1.3. Rising public awareness and increasing healthcare expenses
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cancer immunotherapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research activities in pd1 and pdl1 inhibitors
      • 5.1.3.2. Technological innovations and advancements in cancer screening procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory scenario
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PD-1 & PD-L1 Inhibitors Market, by Product

  • 6.1. Introduction
  • 6.2. Atezolizumab
  • 6.3. Avelumab
  • 6.4. Durvalumab
  • 6.5. Nivolumab
  • 6.6. Pembrolizumab

7. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas PD-1 & PD-L1 Inhibitors Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific PD-1 & PD-L1 Inhibitors Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akeso Inc.
  • 2. Alphamab Oncology
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. BeiGene Ltd.
  • 6. Bristol Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann La Roche Ltd.
  • 9. Gilead Sciences Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Innovent Biologics Inc.
  • 12. Merck KGaA
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Regeneron Pharmaceuticals Inc.
  • 16. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PD-1 & PD-L1 INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023